Why BGPT?
logo

Check the Claims Behind an Author

Review an author's claims as they appear in the record: linked experiments, exact results, limitations, and sources.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Long Explanation



    Career Trajectory and Citation Metrics

    Mircea Ivan (ORCID 0000-0003-3424-6642) is a highly influential molecular biologist whose early work in William Kaelin's laboratory at Brigham and Women's Hospital/Dana-Farber helped define the oxygen-sensing machinery that underpinned the 2019 Nobel Prize in Physiology or Medicine. OpenAlex attributes 184 works and ~17,032 citations (h-index 47) to the matched author profile; the Semantic Scholar-style profile reports h-index 42 with 14,969 citations over 119 papers β€” the discrepancy partly reflects author-disambiguation noise and inclusion of conference abstracts. Two other profiles share the name (h-index 15 and 1), and at least one paper in the dataset β€” a Voronovskaya-type theorem in approximation theory β€” is almost certainly a different Mircea Ivan and should be excluded.

    Foundational Contributions

    His first-author 2001 Science paper demonstrated that HIFΞ± is targeted for VHL-mediated destruction by proline hydroxylation, directly establishing the oxygen-dependence of this post-translational mark . Follow-up first-author work biochemically purified a mammalian HIF prolyl hydroxylase and showed pharmacological inhibition, prefiguring the PHD-inhibitor drug class (roxadustat, daprodustat) . He also co-authored the crystal-structure study of hydroxyproline recognition by pVHL and the VHL-binding/ubiquitination mechanism paper .

    Second Research Program: Hypoxia, microRNAs and Non-coding RNAs

    Later, at Tufts and Indiana University, Ivan pivoted to hypoxic regulation of the non-coding transcriptome. He is senior author of the influential "A MicroRNA Signature of Hypoxia" , the miR-210/ISCU mitochondrial metabolism study , and work connecting hypoxia-driven miRNA downregulation of DNA repair , plus hypoxia-DICER epigenetics, lincNORS sterol homeostasis, NLUCAT1, and the EPHOSS/oxygen-shock stem-cell transplantation discovery in Cell .

    Critical Assessment and Blindspots

    Many highly-cited papers (structure papers, miR-221/222 resistance work) credit Ivan in middle authorship, so first/senior contributions must be parsed carefully; abstract/conference records inflate the 119-184 paper count. Author-name collision with a mathematician contaminates disambiguation. Metabolic/hypoxia work relies heavily on cell-line and murine models (e.g., OIR retinopathy, xenografts), limiting clinical generalizability, and several papers exist only as AACR abstracts without peer-reviewed full data. Citations remain strong (500-950/yr through 2026), indicating durable influence. Confidence: high on metrics, moderate on attribution of specific claims to Ivan's own leadership.



    Feedback:    

    Updated: November 19, 2026

     BGPT Author Review



    Scientific Quality

    90%

    placeholder-removed



    Communication Quality

    70%

    placeholder-removed



    Author Novelty

    90%

    The 2001-2002 hydroxylation discoveries were paradigm-defining; the miRNA-signature-of-hypoxia and EPHOSS findings opened new subfields (hypoxamiRs, oxygen-shock in transplant). Later lncRNA work (lincNORS, NLUCAT1) is novel though less transformative.



    Scientific Rigor

    80%

    Biochemical purification, structural validation, and genetic perturbation approaches in the core papers indicate strong rigor; published in top venues with heavy replication by the field. Deductions for heavy reliance on murine/cell-line models, occasional corrections (e.g., DICER paper correction), and abstract-level claims lacking full datasets.

     Hypothesis Graveyard



    Hypoxia was once thought to regulate gene expression exclusively via HIF transcription factors; Ivan's own miRNA/lncRNA work falsified this by showing extensive post-transcriptional hypoxic regulation independent of transcription.


    'miR-210 is cancer-specific' was an early framing; the signature was subsequently shown in normal cells and ischemic tissues, so miR-210 is a general hypoxia marker, not an oncogenic one.

     Science Art


    Author Review: Mircea Ivan Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT